Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31196295 | 1.00 | NNMT (0.63) | NNMTSMN1; SMN2KDM4EL3MBTL1GRM5 | |
| Hydrochloric Acid SCHEMBL27577287 | 0.98 | NNMT (0.61) | NNMTSMN1; SMN2KDM4EL3MBTL1GRM5 | |
| Bromide SCHEMBL30096685 | 0.98 | NNMT (0.61) | NNMTSMN1; SMN2KDM4EL3MBTL1GRM5 | |
| SCHEMBL8818528 | 0.86 | NNMT (0.49) | NNMTSMN1; SMN2KDM4EL3MBTL1GRM5 | |
| SCHEMBL1515609 | 0.79 | NNMT (0.41) | NNMTSMN1; SMN2KDM4EL3MBTL1MKNK1 | |
| SCHEMBL19581478 | 0.79 | NNMT (0.65) | NNMTSMN1; SMN2KDM4EL3MBTL1GRM5 | |
| SCHEMBL185991 | 0.79 | P4HA1 (0.64) | TSHR | |
| SCHEMBL29524968 | 0.79 | P4HA1 (0.64) | TSHR | |
| SCHEMBL24400225 | 0.77 | NAPRT (0.42) | NNMTSMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL2255291 | 0.77 | NAPRT (0.47) | NNMTSMN1; SMN2KDM4EL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025097247-A1 | METHOD OF TREATMENT OF FIBROSIS WITH INVERSE AGONIST OF RAR RELATED ORPHAN RECEPTORS (RORS) | 11949098 CANADA INC. (CA) | 2025-05-15 | — | — | WO | claimed |
| US-20240383909-A1 | CO-CRYSTALS | INTRA-CELLULAR THERAPIES, INC. | 2024-11-21 | — | — | US | claimed |
| EP-4395767-A2 | CO-CRYSTALS | Intra-Cellular Therapies, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| EP-4243822-A1 | USE OF PHARMACEUTICAL DOSES OF NIACIN, OR AN ANALOG THEREOF, FOR THE REGRESSION OR REVERSAL OF FIBROSIS AND/OR LIVER CIRRHOSIS | The Regents of The University of California (US) | 2023-09-20 | — | — | EP | claimed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | claimed |
| CN-115141292-B | Full-biomass self-assembly single-component intumescent flame retardant and preparation method and application thereof | 福州大学 | 2023-04-14 | — | — | CN | claimed |
| WO-2023034965-A2 | CO-CRYSTALS | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| CN-115141292-A | Full-biomass self-assembly single-component intumescent flame retardant and preparation method and application thereof | 福州大学 | 2022-10-04 | — | — | CN | claimed |
| WO-2022104289-A1 | USE OF PHARMACEUTICAL DOSES OF NIACIN, OR AN ANALOG THEREOF, FOR THE REGRESSION OR REVERSAL OF FIBROSIS AND/OR LIVER CIRRHOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | WO | claimed |
| EP-0491140-B1 | Method for the preparation of substituted and unsbustituted 2,3-pyridine and quinolinedicarboxylic acids | AMERICAN CYANAMID CO (US) | 1997-04-02 | — | — | EP | claimed |
| EP-0584470-B1 | Process for the preparation of 2,3-pyridinedicarboxylic acids from 3-(2-imidazolin-2-yl)picolinic acids | AMERICAN CYANAMID CO (US) | 1995-08-16 | — | — | EP | claimed |
| US-5378843-A | Halogenation, quaternization | AMERICAN CYANAMID COMPANY (US) | 1995-01-03 | — | — | US | claimed |
| US-5371229-A | Nitric acid oxidation of substituted quinoline precursor using manganese catalyst | AMERICAN CYANAMID COMPANY (US) | 1994-12-06 | — | — | US | claimed |
| EP-0594993-A1 | Method for the preparation of 2,3-pyridine-dicarboxylic acids and derivatives thereof | AMERICAN CYANAMID COMPANY (US) | 1994-05-04 | — | — | EP | claimed |
| EP-0584470-A1 | Process for the preparation of 2,3-pyridinedicarboxylic acids from 3-(2-imidazolin-2-yl)picolinic acids | AMERICAN CYANAMID COMPANY (US) | 1994-03-02 | — | — | EP | claimed |
| US-5250694-A | Process for the preparation of 2,3-pyridine-dicarboxylic acids from 3-(2-imidazolin-2-yl)picolinic acids | AMERICAN CYANAMID COMPANY (US) | 1993-10-05 | — | — | US | claimed |
| EP-0548532-A1 | 5,6-Disubstituted-3-pyridylmethyl ammonium halide compounds useful for the preparation of 5-(substituted methyl)-2,3-pyridinedicarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1993-06-30 | — | — | EP | claimed |
| EP-0491140-A1 | Method for the preparation of substituted and unsbustituted 2,3-pyridine and quinolinedicarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1992-06-24 | — | — | EP | claimed |
| US-5122608-A | Hydrolysis ofa 2,3-pyridine- or quinolinedicarboxylic acid diester with water and a acid having an ionization constant of 3; treating with a base and separating | AMERICAN CYANAMID COMPANY (US) | 1992-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | COL1A1, COL2A1, FN1 | NNMT 11/4885SMN1; SMN2 1124/4885KDM4E 3141/4885 |
| US-20240383909-A1 | CO-CRYSTALS | NT5C3B, PRNP, MTAP | NNMT 1917/4885SMN1; SMN2 4001/4885KDM4E 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.